Company intelligence / Profile preview

HMNC Brain Health

Ownership: Private
Development stage: Other

Overview

Promising top-line results from Phase 2 Proof-of-Concept trial of oral prolonged-release ketamine (KET01) in Treatment-Resistant Depression, showing suggested clinically relevant improvement in efficacy with good safety and tolerability profile[5]

Therapeutic areas: Psychiatry
Modalities: Oral prolonged-release formulation (for ketamine)AI-powered companion diagnostics
Industry: Biotech

Drug pipeline

1 asset

nelivaptan

Discontinued

Partnerships

Develco Pharma

Beyond the preview

Go deeper on HMNC Brain Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMNC Brain Health.